Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors

Current Oncology Reports

Volumn 10, Issue 1, 2008, Pages 18-26

  Brufsky, Adam M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CAPECITABINE; CLODRONIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN; EXEMESTANE; GLUCOCORTICOID; GOSERELIN; HORMONE RECEPTOR; IBANDRONIC ACID; LETROZOLE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BACKACHE; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COUGHING; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY CANCER; FATIGUE; FEMALE; FLU LIKE SYNDROME; FRAGILITY FRACTURE; HOT FLUSH; HUMAN; INSOMNIA; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; LIMB PAIN; MONOTHERAPY; MYALGIA; NAUSEA; NONHUMAN; OSTEOPOROSIS; OVERALL SURVIVAL; PERIPHERAL EDEMA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; URINARY TRACT INFECTION; WOMEN'S HEALTH;

AROMATASE INHIBITORS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; PREVALENCE; RISK FACTORS;

EID: 38149052800     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0005-z     Document Type: Review

References (42)

1. Paterson AH: The role of bisphosphonates in early breast cancer. Oncologist 2006, 11:13-19.
2. Chien AJ, Goss PE: Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 2006, 24:5305-5312.
3. Coates AS, Keshaviah A, Thürlimann B, et al.: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25:486-492.
4. Coombes RC, Kilburn LS, Snowdon CF, et al.: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369:559-570.
5. Howell A, Cuzick J, Baum M, et al.: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
6. Jakesz R, Jonat W, Gnant M, et al.: Switching of post-menopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366:455-462.
7. Goss PE, Ingle JN, Martino S, et al.: Randomized trial of letrozole following tanioxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97:1262-1271.
8. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 2.2007). 2007 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed August 25, 2007.
9. Brufsky A, Harker WG, Beck JT, et al.: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007, 25:829-836.
10. Brufsky A, Lund K, Cobb P, et al.: Twenty-four month follow-up of the effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole [abstract S060]. Presented at the 29th San Antonio Breast Cancer Symposium. San Antonio, TX; December 14-17, 2006.
11. Brufsky A, Bundred N, Coleman R, et al.: Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2007, [In press].
12. Bundred N, Campbell I, Coleman R, et al.: Zoledronic acid in the prevention of cancer treatment-induced bone loss in post-menopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study) [abstract 12]. Presented at the 5th European Breast Cancer Conference. Nice, France; March 21-25, 2006.
13. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al.: Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-response breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820-828.
14. Verdijk R, Franke HR, Wolbers F, Vermes I: Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 2007, 246:308-312.
15. Van der Pluijm G, Vloedgraven H, van Beek E, et al.: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996, 98:698-705.
16. Wood J, Bonjean K, Ruetz S, et al.: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061.
17. Saarto T, Blomqvist C, Virkkunen P, et al.: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001, 19:10-17.
18. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C: Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004, 43:650-656.
19. Powles T, Paterson S, Kanis JA, et al.: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002, 20:3219-3224.
20. Powles T, Paterson A, McCloskey E, et al.: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006, 8:R13.
21. Kokufu I, Kohno N, Takao S, et al.: Adjuvant pamidronate (PMT) therapy for the prevention of bone metastasis in breast cancer (BC) patients (pts) with four or more positive nodes [abstract 530]. J Clin Oncol 2004, 22(14S):10s.
22. Michaud LB, Goodin S: Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm 2006, 63:419-430.
23. Taube T, Elomaa I, Blomqvist C, et al.: Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 1994, 15:161-166.
24. Eastell R, Hannon RA, Cuzick J, et al.: Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006, 21:1215-1223.
25. Geisler J, Lonning PE, Krag LE, et al.: Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006, 42:2968-2975.
26. Gonnelli S, Cadirni A, Caffarelli C, et al.: Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 2007, 40:205-210.
27. Perez EA, Josse RG, Pritchard KI, et al.: Effect of letrozole vs placebo on bone mineral density in women with primary beast cancer completing 5 or more years of adjuvant tamoxifen. A companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629-3635.
28. Asmar L, Negron AG, Stokoe CT, et al.: The effect of tamoxifen or exemestane on bone mineral density after 2 years of adjuvant treatment of postmenopausal women with early breast cancer [abstract 2102]. Presented at the 29th San Antonio Breast Cancer Symposium. San Antonio, TX December 14-17, 2006.
29. Coleman RE on behalf of the ATAC Trialists' Group: Effect of anastrozole on bone mineral density: 5-year results from the "Arimidex," Tamoxifen, Alone or Combination (ATAC) trial [abstract 511]. J Clin Oncol 2006, 24(18S):5s.
30. Coleman RE, Banks LM, Girgis S, et al.: Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study. Lancet Oncol 2007, 8:119-127.
31. Goss PE, Qi S, Josse RG, et al.: The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004, 34:384-392.
32. Goss PE, Qi S, Cheung AM, et al.: Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rates. Clin Cancer Res 2004, 10:5717-5723.
33. Clinical trials. National Cancer Institute website. http://www.cancer.gov/clinicaltrials. Accessed October 9, 2007.
34. Yoneda K, Tanji Y, Okishiro M, et al.: Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: is there a racial difference? Ann Oncol 2006, 17:1175-1176.
35. Mincey BA, Duh MS, Thomas SK, et al.: Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 2006, 7:127-132.
36. Wallace BA, Cumming RG: Systemic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women. Calcif Tissue Int 2000, 67:10-18.
37. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE: Effect of calcium and vitamin D on bone density in men and women 65 years of age or older. N Engl J Med 1997, 337:670-676.
38. Fosamax [package insert]. Whitehouse Station, NJ: Merck & Co. Inc.; 2006.
39. Actonel [package insert]. Cincinnati, OH: Procter & Gamble Pharmaceuticals Inc.; 2006.
40. Boniva [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2006.
41. Delmas PD, Balena R, Confravreux E, et al.: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997, 15:955-962.
42. Waltman NL, Twiss JJ, Ott CD, et al.: Testing an intervention for preventing osteoporosis in postmenopausal breast cancer survivors. J Nurs Scholarsh 2003, 35:333-338.